The Korean Practice Parameter for the Treatment of Pervasive Developmental Disorders: Pharmacological Treatment.
- Author:
In Hee CHO
1
;
Hanik K YOO
;
Jung Woo SON
;
Hee Jeong YOO
;
Young Jin KOO
;
Un Sun CHUNG
;
Dong Hyun AHN
;
Joung Sook AHN
Author Information
1. Department of Psychiatry, Gachon University of Medicine and Science, Incheon, Korea.
- Publication Type:Controlled Clinical Trial ; Review ; Clinical Trial
- Keywords:
Pervasive Developmental Disorders;
Practice Parameter;
Pharmacological Treatment
- MeSH:
Adolescent;
Antidepressive Agents;
Autistic Disorder;
Child;
Education;
Humans;
Methylphenidate;
Quality of Life;
Risperidone;
Serotonin
- From:Journal of the Korean Academy of Child and Adolescent Psychiatry
2007;18(2):109-116
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The objective of this review is to establish practice parameters for pharmacological treatment of children and adolescents with pervasive developmental disorders. We performed a detailed review of the literature, including a wide range of controlled clinical trials, open trials, case reports, and side-effect profiles of related drugs. Few medications have a treatment indication for pervasive developmental disorders, and few studies with well-controlled methodology are available for evaluating treatment results. Pharmacological treatments focus on associated target symptoms because symptom reduction may improve educational and social ability and enhance quality of life. Well-controlled trials have been conducted for some SSRI(selective serotonin reuptake inhibitor) antidepressants, risperidone, and methylphenidate, and showed reduction of some target symptoms. Since the medications are not specific to autism and do not treat core symptoms of the disorder, their potential side effects should be carefully considered. Family education is necessary to give proper information on target symptoms, limitation of drug treatments, and risks.
